Mitochondrial Peptides: MOTS-c, Humanin, and SS-31

What Are Mitochondrial-Derived Peptides?

Mitochondrial-derived peptides (MDPs) are a recently discovered class of bioactive peptides encoded within the mitochondrial genome. This discovery challenged the long-held belief that mitochondrial DNA (mtDNA) only encoded 13 proteins involved in the electron transport chain. We now know that the mitochondrial genome also contains small open reading frames (sORFs) that produce biologically active peptides with profound effects on metabolism, cell survival, and aging.

The three most studied mitochondrial-derived peptides are Humanin, MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c), and SHLPs (Small Humanin-Like Peptides). Additionally, the synthetic peptide SS-31 (Elamipretide) targets mitochondrial function and is included in this discussion for its therapeutic relevance.

MOTS-c: The Exercise Mimetic Peptide

Discovery and Structure

MOTS-c was discovered in 2015 by Dr. Changhan Lee and colleagues at the University of Southern California. It is a 16-amino acid peptide encoded in the 12S rRNA gene of the mitochondrial genome.

Mechanisms and Benefits

MOTS-c has been called an "exercise mimetic" because it activates many of the same metabolic pathways as physical exercise:

• AMPK activation: MOTS-c activates AMP-activated protein kinase, the master metabolic regulator that is also activated by exercise and caloric restriction
• Glucose metabolism: Improves insulin sensitivity and glucose uptake in skeletal muscle
• Fat metabolism: Promotes fatty acid oxidation and reduces fat accumulation
• Nuclear translocation: MOTS-c can translocate from mitochondria to the nucleus under metabolic stress, directly regulating gene expression
• Epigenetic regulation: Influences gene expression through folate-methionine cycle modulation

Research Findings

Preclinical studies with MOTS-c have demonstrated:

• Prevention of diet-induced obesity in mice
• Improved physical performance and endurance
• Reversal of age-dependent insulin resistance
• Protection against age-related metabolic decline
• MOTS-c levels decline with age and are lower in individuals with metabolic disease

Humanin: The Cytoprotective Peptide

Discovery

Humanin was discovered in 2001 from the brain of an Alzheimer's disease patient as a peptide that could protect neurons from amyloid-beta toxicity. It is a 24-amino acid peptide encoded in the 16S rRNA gene of the mitochondrial genome.

Protective Effects

• Neuroprotection: Protects against amyloid-beta toxicity, oxidative stress, and other neurodegenerative insults
• Cytoprotection: Prevents apoptosis (programmed cell death) in response to various stressors
• Metabolic regulation: Improves insulin sensitivity and reduces hepatic glucose production
• Cardiovascular protection: Protects against atherosclerosis and cardiac ischemia-reperfusion injury in animal models
• Longevity association: Higher humanin levels correlate with exceptional longevity in centenarian studies

Humanin and Aging

Circulating humanin levels decline with age in both humans and animal models. This decline is associated with increased susceptibility to age-related diseases. Research suggests that maintaining or restoring humanin levels may counteract multiple aspects of aging simultaneously.

SS-31 (Elamipretide): Targeting Mitochondrial Cardiolipin

What Is SS-31?

SS-31, also known as elamipretide or Bendavia, is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively targets the inner mitochondrial membrane by binding to cardiolipin, a phospholipid essential for mitochondrial function.

Mechanism of Action

• Stabilizes cardiolipin and prevents its oxidation
• Optimizes electron transport chain efficiency
• Reduces mitochondrial reactive oxygen species (ROS) production
• Prevents mitochondrial permeability transition pore opening
• Improves ATP production while reducing oxidative damage

Clinical Development

SS-31 is one of the most advanced mitochondrial peptides in clinical development:

• Clinical trials for Barth syndrome (a mitochondrial cardiomyopathy)
• Studies in age-related macular degeneration
• Research in heart failure and renal disease
• Investigations into age-related skeletal muscle decline

Small Humanin-Like Peptides (SHLPs)

Six small humanin-like peptides (SHLP1-6) have been identified in the mitochondrial genome. While less studied than humanin and MOTS-c, preliminary research suggests they have diverse biological activities including:

• SHLP2 and SHLP3 have neuroprotective properties similar to humanin
• SHLP2 improves mitochondrial metabolism
• SHLP6 promotes cell death, suggesting it may have anti-tumor properties

Implications for Aging and Disease

Mitochondrial-derived peptides represent a paradigm shift in our understanding of mitochondrial biology. They suggest that mitochondria are not just power plants but active signaling organelles that communicate with the rest of the cell and even other tissues through peptide signals. The age-related decline in these peptides may be a fundamental driver of aging and age-related disease.

Conclusion

Mitochondrial-derived peptides are among the most exciting discoveries in peptide biology in recent years. Their potential to address metabolic disease, neurodegeneration, cardiovascular disease, and aging itself makes them a focus of intense research activity. As clinical trials progress and our understanding deepens, these peptides may become powerful tools for promoting healthy aging and treating some of the most challenging diseases of our time.